Lost response to your UC biologic? Here's how to navigate what comes next.

What your UC lab results actually mean and how to use them.

Your guide to proctitis treatment, progression risk, and why it's not 'mild.'

Why UC changes how you see yourself, and what actually helps.

Why UC drains your iron and what to do about it.

Flare or bug? How to tell the difference and what to tell your doctor.

How UC trains your brain to fear food, and how to break the cycle.

How to stay ahead of dehydration during UC flares and know when to get help.

Which UC rectal therapy works where, and how to use each one effectively.

Recognize pouchitis symptoms early and understand your treatment options after J-pouch surgery.

Decode your UC colonoscopy report in plain language.

What to do when you catch a cold or flu while on UC immunosuppressants.

Practical colonoscopy prep tips made for ulcerative colitis patients.

What clinical trials actually show about cannabis and CBD for ulcerative colitis.

What to expect day by day if a severe UC flare lands you in the hospital.

What the research actually says about alcohol, smoking, vaping, and cannabis with UC.

Learn why UC causes fatigue, weight loss, fever, and pain beyond the gut.

Exactly what to track in your UC symptom diary and why each data point matters.

What treat-to-target means for your IBD care and why feeling fine is not enough.

Why IBD gets missed after 50 and what older patients need to know about treatment.

Your biologic got denied. Here is how to fight back and win your appeal.

Evidence-based ways to break the IBD stress-flare cycle and regain control.

What you can actually eat with UC, one food at a time.

What clinical trials actually say about vitamin D, curcumin, omega-3s, and probiotics for IBD.

Honest advice on dating, intimacy, and partner communication with UC.

What the research says about the IBD diet advice flooding your feed.

What to do, what to skip, and how to adjust exercise for your UC.

Practical guidance for partners of people with Crohn's or colitis.

How to find the right gastroenterologist and navigate UC care decisions.

Your food diary failed for reasons that have nothing to do with willpower.

Practical scripts for explaining UC to friends, family, and coworkers.

Which labs to request, what your levels should be, and how to replenish safely.

What UC patients need to know about medication safety, flares, and planning a healthy pregnancy.

Which probiotics actually have UC evidence, and what the research says about the rest.

Your complete toolkit for daily UC logistics, from legal rights to emergency kits.

Why UC wrecks your sleep and what actually helps.

Plan travel with UC confidently: medications, insurance, restrooms, and emergency prep.

How the gut-brain axis drives UC anxiety, and what actually helps.

Practical guide to navigating college, career, and independence with UC.

Know which UC complications are emergencies and which need steady monitoring.

Find the right UC support community and know what to watch for.

What's real and what's hype in UC research right now.

Which UC trigger foods actually cause inflammation, and which just cause discomfort?

How UC diagnosis, treatment, and monitoring differ when you're over 60.

What parents need to know about pediatric UC, from diagnosis to teen self-management.

What the data actually says about your UC prognosis, from life expectancy to surgery rates.

Which vaccines are safe on your UC meds, and which ones need to wait.

Why UC develops and what you can actually do about the risk factors.

Everything newly diagnosed UC patients need to know, in plain language.

Your complete guide to workplace rights, accommodations, and protections with UC.

Comparing biologic classes for UC, from anti-TNFs to the newest IL-23 inhibitors.

Urgency, tenesmus, and incontinence with UC. What the evidence says helps.

Recognize early UC symptoms and know when to push for a diagnosis.

What the evidence says about staying in UC remission and catching flares early.

Understand every test in the UC diagnostic workup and what your results mean.

When and why immunosuppressants are used for UC, and what to expect.

How JAK inhibitors and S1P modulators work, their risks, and how they compare.

Comparing mesalamine formulations, side effects, and whether you can stop in remission.

A complete guide to managing UC treatment costs, insurance, and financial aid.

A practical guide to prednisone for UC: side effects, tapering, and alternatives.

What clinical trials actually show about supplements and alternative UC treatments.

Learn how your UC type affects treatment, monitoring, and outlook.

Learn which UC symptoms show up outside your gut and when to act.

Every UC diet compared side by side: evidence, difficulty, and when to use each one.

Your complete guide to UC surgery options, recovery, and life after.

Learn what each UC symptom means for your disease and when to call your GI.

How UC and its treatments affect male fertility, testosterone, and sexual health.

Understand the real differences between UC, Crohn's, IBS, and other forms of colitis.

A step-by-step plan for handling UC flares, from first symptoms to recovery.

Stage-by-stage meals for UC flares, from liquids-only to recovery.

How UC interacts with your cycle, birth control, and menopause.

Your guide to UC cancer screening timelines, dysplasia, and risk reduction.

Tremfya and Stelara are two Johnson & Johnson IL-23 pathway biologics for moderate-to-severe ulcerative colitis. Stelara has been the established UC option since its UNIFI-based approval, while Tremfya received UC approval in 2024 based on the QUASAR and ASTRO trials. The drugs differ in mechanism. Tremfya selectively blocks IL-23 through p19, while Stelara blocks both IL-12 and IL-23 through p40. For Crohn's, GALAXI 2 and 3 demonstrated Tremfya's superiority over Stelara on endoscopic endpoints. UC patients often ask whether similar logic applies to their disease. This guide walks through the tremfya vs stelara ulcerative colitis decision.

Tremfya and Remicade take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Remicade is the original anti-TNF for UC, with an efficacy record stretching back to ACT-1 and ACT-2 in the mid-2000s. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, offering both IV and fully subcutaneous induction pathways. UC patients commonly weigh these two drugs when choosing a first biologic or switching after loss of response. This guide walks through the tremfya vs remicade ulcerative colitis decision.

Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis, both newly approved for the indication. Omvoh gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2. Tremfya gained UC approval in September 2024 based on QUASAR and ASTRO. Patients comparing these two within-class UC options often weigh induction flexibility, urgency outcomes, and maintenance dosing. This guide walks through the tremfya vs omvoh ulcerative colitis comparison.

Tremfya and Humira are two biologics for moderate-to-severe ulcerative colitis that take fundamentally different mechanistic approaches. Humira is the established anti-TNF with more than a decade of UC experience. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials, which uniquely offers both subcutaneous and intravenous induction pathways. UC patients choosing between these drugs weigh mechanism, administration flexibility, and long-term safety. This guide walks through the tremfya vs humira ulcerative colitis decision.

Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the tremfya vs entyvio ulcerative colitis comparison.

Stelara and Remicade are two commonly used biologics for moderate-to-severe ulcerative colitis, and both start with an intravenous infusion. Beyond that shared starting point, they work differently, have different safety profiles, and come with very different maintenance schedules. Patients typically weigh them when starting a first biologic, switching after anti-TNF failure, or looking at long-term infection risk. This guide walks through the evidence UC patients need to make an informed stelara vs remicade ulcerative colitis decision with their gastroenterologist.

Stelara and Humira are two of the most common biologics discussed when ulcerative colitis patients are starting a first biologic or looking for a next step after losing response. Humira is a long-established anti-TNF. Stelara is an IL-12/23 blocker that arrived in UC much more recently. They work through different immune pathways, come with different dosing schedules, and differ meaningfully on safety. This guide walks through the evidence UC patients need to make an informed stelara vs humira ulcerative colitis decision with their gastroenterologist.

Skyrizi and Tremfya are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis. Skyrizi gained UC approval in June 2024 based on INSPIRE and COMMAND. Tremfya gained UC approval in September 2024 based on QUASAR and ASTRO. Patients comparing these two within-class UC options often weigh induction flexibility, maintenance dosing, and trial design. This guide walks through the skyrizi vs tremfya ulcerative colitis comparison.

Skyrizi and Stelara are two interleukin-pathway biologics increasingly used for moderate-to-severe ulcerative colitis. Skyrizi gained UC approval in June 2024, joining Stelara in the IL-23 targeting category. The two drugs take meaningfully different approaches. Skyrizi blocks only IL-23. Stelara blocks both IL-12 and IL-23. For Crohn's, the SEQUENCE head-to-head trial showed Skyrizi's p19 selectivity outperformed Stelara on endoscopic endpoints, and UC patients often want to know whether similar logic applies to their disease. This guide walks through the current evidence and practical considerations for the skyrizi vs stelara ulcerative colitis decision.

Skyrizi and Remicade represent two very different approaches to treating moderate-to-severe ulcerative colitis. Remicade has been the anti-TNF standard for UC since the mid-2000s. Skyrizi is a newer IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND trials. Patients commonly compare these drugs when starting a first biologic or considering alternatives after Remicade has lost effect. This guide walks through the skyrizi vs remicade ulcerative colitis decision.

Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis. Omvoh gained UC approval first in October 2023 based on LUCENT-1 and LUCENT-2. Skyrizi followed in June 2024 based on INSPIRE and COMMAND. Patients comparing these two within-class UC options often weigh maintenance dosing, bowel urgency outcomes, and trial design. This guide walks through the skyrizi vs omvoh ulcerative colitis comparison.

Skyrizi and Humira are two AbbVie biologics for moderate-to-severe ulcerative colitis, but they work through very different mechanisms. Humira is the established anti-TNF standard with more than a decade of UC experience. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on the INSPIRE induction and COMMAND maintenance trials. For UC patients choosing between these drugs, the decision often comes down to mechanism, administration preferences, and expected long-term safety. This guide walks through the skyrizi vs humira ulcerative colitis decision.

Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs but through very different mechanisms. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing its superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or are looking for alternatives to anti-TNF therapy. This guide walks through the skyrizi vs entyvio ulcerative colitis comparison.

Simponi and Tremfya represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for UC in September 2024 based on QUASAR and ASTRO. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with distinctive induction flexibility. This guide walks through the simponi vs tremfya ulcerative colitis comparison.

Simponi and Stelara are two subcutaneous biologics for moderate-to-severe ulcerative colitis that work through fundamentally different mechanisms. Simponi (golimumab) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the simponi vs stelara ulcerative colitis decision.

Simponi and Skyrizi represent two different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Skyrizi (risankizumab) is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the simponi vs skyrizi ulcerative colitis comparison.

Simponi and Remicade are two anti-TNF biologics for moderate-to-severe ulcerative colitis that take different administration routes. Simponi (golimumab) is a subcutaneous injection. Remicade (infliximab) is an intravenous infusion. Both block TNF-alpha, so their mechanisms are closely related, but the administration difference and dose escalation options shape the practical comparison. This guide walks through the simponi vs remicade ulcerative colitis decision.

Simponi and Omvoh represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2, making it the first IL-23 p19-selective biologic approved for UC. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and distinctive urgency data. This guide walks through the simponi vs omvoh ulcerative colitis comparison.

Simponi and Humira are two subcutaneous anti-TNF biologics for moderate-to-severe ulcerative colitis. Both block TNF-alpha through fully human IgG monoclonal antibody structures, so their mechanisms are closely related. The main practical differences come down to dosing frequency (monthly for Simponi vs every other week for Humira), biosimilar availability, and trial data. This guide walks through the simponi vs humira ulcerative colitis comparison.

Simponi and Entyvio take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic that targets alpha-4-beta-7 integrin. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with favorable systemic safety. This guide walks through the simponi vs entyvio ulcerative colitis comparison.

Omvoh and Stelara both target IL-23 pathway inflammation in moderate-to-severe ulcerative colitis, but with different mechanism specificity and clinical profiles. Stelara is an IL-12/23 p40 biologic approved for UC in October 2019 based on UNIFI. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on LUCENT-1 and LUCENT-2. Patients choosing between these two non-anti-TNF IL-23 pathway drugs often weigh mechanism specificity, urgency outcomes, and long-term dosing. This guide walks through the omvoh vs stelara ulcerative colitis decision.

Omvoh and Remicade represent two very different approaches to treating moderate-to-severe ulcerative colitis. Remicade has been the anti-TNF standard for UC since the mid-2000s. Omvoh is a newer IL-23 p19-selective biologic that gained UC approval in October 2023 based on the LUCENT-1 and LUCENT-2 trials. Patients commonly compare these drugs when starting a first biologic or considering alternatives after Remicade has lost effect. This guide walks through the omvoh vs remicade ulcerative colitis decision.

Omvoh and Humira take different mechanistic approaches to moderate-to-severe ulcerative colitis. Humira is the established anti-TNF with more than a decade of UC experience. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials, making it the first drug in its class approved for UC. Patients choosing between these drugs weigh mechanism, safety, and long-term administration convenience. This guide walks through the omvoh vs humira ulcerative colitis decision.

Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the omvoh vs entyvio ulcerative colitis comparison.

Humira and Remicade are the two most widely prescribed anti-tumor necrosis factor (anti-TNF) biologics for ulcerative colitis. Both have treated moderate-to-severe UC for more than fifteen years, both are now available as lower-cost biosimilars, and both can help patients reach steroid-free remission. The choice between them usually comes down to how you want to receive your medication, how your insurance handles biosimilars, and which practical trade-offs fit your life. This guide walks through what UC patients typically weigh when deciding between humira vs remicade ulcerative colitis therapy.

Entyvio and Stelara are two of the most common biologics used for ulcerative colitis after a patient has failed an anti-TNF, and they are increasingly considered first-line options as well. Both avoid the systemic TNF blockade that raises infection risk in anti-TNF therapy, but they do so through very different mechanisms. Entyvio is gut-selective. Stelara blocks an upstream cytokine pathway that affects inflammation throughout the body. For UC patients weighing a second-line biologic or looking for a safer first-line option, the decision often hinges on onset of action, efficacy in anti-TNF experienced patients, and dosing convenience. This guide walks through the evidence UC patients need to make an informed entyvio vs stelara ulcerative colitis decision.

Entyvio and Remicade are the two most commonly used intravenous biologics for ulcerative colitis. Remicade is a broad anti-tumor necrosis factor agent with decades of real-world data. Entyvio is a gut-selective biologic that acts almost exclusively on the intestines. For UC patients who want infusion-based therapy but are weighing targeted vs systemic action, this is a common comparison. This guide walks through the evidence on entyvio vs remicade ulcerative colitis across mechanism, efficacy, safety, and practical considerations.

Entyvio and Humira are two of the most commonly prescribed biologics for ulcerative colitis, and they represent very different approaches to quieting inflammation. Humira is a systemic anti-TNF that affects immune signaling throughout the body. Entyvio is gut-selective and acts almost exclusively in the intestines. Uniquely for biologic comparisons in UC, there is direct head-to-head randomized trial data. The VARSITY trial compared these two drugs directly, and the results have meaningfully shaped how gastroenterologists think about first-line biologic choice in UC. This guide walks through the evidence patients need to make an informed entyvio vs humira ulcerative colitis decision.